Hyperpituitarism: Clinical Trials

36 trials for Hyperpituitarism, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

36 completed. 36 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 336Completed 36
Phase 21Completed 1

Follow Hyperpituitarism: new trials by email Literature Review of Hyperpituitarism trials Research Report on Hyperpituitarism

Trials (filtered) newest first · largest first

All 36 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
Pegvisomant - Pituitary Disease
Phase 3CompletedEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)122019-10-212025-11-06
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
CAM2029 (octreotide subcutaneous depot) - Acromegaly
Phase 3CompletedCamurus AB1352019-10-102025-12-22
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
CAM2029 (octreotide subcutaneous depot), Matching placebo - Acromegaly
Phase 3CompletedCamurus AB722019-08-192026-08-20
Open-label Treatment in Cushing's Syndrome
Levoketoconazole - Cushing Syndrome, Cushing Disease
Phase 3CompletedCortendo AB512019-01-072025-06-19
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
Relacorilant, Placebo - Cushing Syndrome
Phase 3CompletedCorcept Therapeutics1522018-11-152025-07-16
Strict IGF-1 Control in Acromegaly
Pegvisomant - Acromegaly
Phase 3CompletedUnity Health Toronto102017-07-272021-11-22
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
osilodrostat, osilodrostat Placebo - Cushing's Disease
Phase 3CompletedNovartis Pharmaceuticals732016-10-032021-11-01
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
Octreotide capsules - Acromegaly
Phase 3CompletedChiasma, Inc.1462016-02-012022-04-22
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Pasireotide LAR - Acromegaly
Phase 3CompletedNovartis Pharmaceuticals1232015-03-312019-12-10
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
Lanreotide Autogel®, Lanreotide Acetate - Acromegaly
Phase 3CompletedIpsen1282014-10-012019-01-29
Treatment for Endogenous Cushing's Syndrome
Levoketoconazole - Endogenous Cushing's Syndrome
Phase 3CompletedCortendo AB942014-08-012021-04-19
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
Octreotide capsules - Acromegaly
Phase 3CompletedChiasma, Inc.1552012-03-012017-08-17
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg - Cushing's Disease
Phase 3CompletedNovartis Pharmaceuticals1502011-11-042018-05-22
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
Pasireotide sub-cutaneous - Cushing's Disease
Phase 3CompletedNovartis Pharmaceuticals1042011-08-162018-06-19
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
Mifepristone - Cushing's Disease, Cushing's Syndrome
Phase 3CompletedCorcept Therapeutics42010-11-012014-03-18
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg - Acromegaly
Phase 3CompletedNovartis Pharmaceuticals1982010-07-192018-04-05
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
mifepristone - Cushing's Syndrome
Phase 3CompletedCorcept Therapeutics302009-07-012014-04-02
Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia
Calcium and Vitamin D, Placebo - Risperidone-induced Hyperprolactinemia
Phase 3CompletedChadi A. Calarge472008-11-012017-12-26
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Lanreotide autogel 120 mg - Acromegaly
Phase 3CompletedIpsen1082008-05-012022-10-14
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
Pasireotide, Octreotide - Acromegaly
Phase 3CompletedNovartis Pharmaceuticals3582008-02-112017-07-02

Showing 20 of 36. Sign in to see all of them.

Narrower conditions

Acromegaly (23)  ·  Pituitary ACTH Hypersecretion (11)  ·  Cushing Syndrome (5)  ·  Pituitary Diseases (5)  ·  ACTH Syndrome, Ectopic (4)  ·  Pituitary Neoplasms (3)  ·  Adrenal Cortex Neoplasms (2)  ·  Choristoma (2)  ·  Gigantism (2)  ·  Hirsutism (2)  ·  ACTH-Secreting Pituitary Adenoma (1)  ·  Adenoma (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Fibrous Dysplasia, Polyostotic (1)  ·  Growth Disorders (1)

Broader conditions

Brain Diseases (36)  ·  Central Nervous System Diseases (36)  ·  Endocrine System Diseases (36)  ·  Hypothalamic Diseases (36)  ·  Nervous System Diseases (36)  ·  Pituitary Diseases (31)  ·  Bone Diseases (24)  ·  Bone Diseases, Endocrine (24)  ·  Musculoskeletal Diseases (24)  ·  Neoplasms (9)  ·  Endocrine Gland Neoplasms (6)  ·  Neoplasms by Site (6)  ·  Adrenal Gland Diseases (5)  ·  Adrenocortical Hyperfunction (5)

Interventions

lanreotide (7)  ·  pasireotide (5)  ·  pegvisomant (5)  ·  Octreotide (4)  ·  Corlux (3)  ·  Mifepristone (3)  ·  Duration of Therapy (2)  ·  Cabergoline (1)  ·  Calcium (1)  ·  Osilodrostat (1)  ·  Suspensions (1)  ·  Vitamin D (1)  ·  relacorilant (1)

Sponsors

Novartis Pharmaceuticals (9)  ·  Ipsen (8)  ·  Corcept Therapeutics (4)  ·  Ambrilia Biopharma, Inc. (2)  ·  Camurus AB (2)  ·  Chiasma, Inc. (2)  ·  Cortendo AB (2)  ·  Chadi A. Calarge (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  National Institute of Dental and Craniofacial Research (NIDCR) (1)  ·  Novartis (1)  ·  Pfizer (1)  ·  Seth Gordhandas Sunderdas Medical College (1)  ·  Unity Health Toronto (1)

Countries

United States (21)  ·  Italy (16)  ·  Germany (15)  ·  Spain (13)  ·  France (12)  ·  Poland (12)  ·  United Kingdom (11)  ·  Hungary (10)  ·  Turkey (Türkiye) (10)  ·  Netherlands (9)  ·  Romania (9)  ·  Belgium (8)  ·  Canada (8)  ·  Greece (8)  ·  Russia (8)

Top investigators

Raphael Naudin, M.D. (2)  ·  Andreas Moraitis, MD (1)  ·  Chadi Calarge, M.D. (1)  ·  Coleman Gross (1)  ·  Coleman Gross, M.D. (1)  ·  Coleman Gross, MD (1)  ·  Constance Chik, MD (1)  ·  Diego Ferone, M.D (1)  ·  Fredric Cohen, MD (1)  ·  Fredric J Cohen, MD (1)  ·  Karim A Calis, Pharm.D. (1)  ·  Maria Fleseriu, M.D., FACE (1)

Results publications

PMID 25013998, PMID 26507877, PMID 40418492, PMID 18248639, PMID 19542735, PMID 19639415, PMID 19898989, PMID 21086246, PMID 21148630, PMID 21212103, PMID 22397653, PMID 22466348, PMID 23746264, PMID 23970725, PMID 24287689, PMID 24423301, PMID 25103549, PMID 25260838, PMID 25537481, PMID 25664604, PMID 26437217, PMID 26603536, PMID 27039081, PMID 27405306, PMID 28289402, PMID 29032078, PMID 29112461, PMID 31379734, PMID 31465533, PMID 31542384, PMID 31804965, PMID 31875276, PMID 32117045, PMID 32217809, PMID 32366244, PMID 32385851, PMID 33216275, PMID 33897615, PMID 34173129, PMID 34953531, PMID 35058882, PMID 35325149, PMID 39378125, PMID 39610378, PMID 41052284, PMID 41730814

NIH funding

2019 (2), 2004 (1), 2009 (1), 2014 (1), 2015 (1), K23MH085005 (1)